Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ...

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted ...

Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years AstraZeneca’s TAGRISSO®(osimertinib) has been approved in the ...

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer. The Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for adults ...

British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...

Three months later, the FDA has added its acclamation, signing off on Tagrisso to become the first targeted therapy for unresectable, stage 3 epidermal growth factor receptor-mutated (EGFRm ...

Tagrisso reduces disease progression or death risk by 84% compared to placebo. More than 200,000 people are diagnosed with lung cancer in the U.S. each year, with NSCLC being the most common type ...

Based on LAURA Phase III trial results which showed Tagrisso Tagrisso reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio 0.16; 95% confidence interval 0.10-0 ...

Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years WILMINGTON, Del., September 26, 2024--(BUSINESS WIRE)--AstraZeneca ...